Alkem Laboratories Declines 4.48%: 3 Key Technical Shifts Shape the Week

1 June: Open Interest Surge Amid Bearish Price Action

Alkem Laboratories saw a notable 10.22% increase in open interest in its derivatives segment, rising from 17,320 to 19,090 contracts. This surge was accompanied by robust trading volumes, with 19,824 contracts traded and a combined derivatives value exceeding ₹20,332.42 lakhs. Despite this heightened activity, the stock price declined sharply by 3.29% to Rs.5,317.00, underperforming the Pharmaceuticals & Biotechnology sector and the Sensex.

The price action on this day was bearish, with the stock touching an intraday low of Rs.5,280 and trading near this level for much of the session. Technical indicators confirmed a downtrend, with the stock trading below all key moving averages. The increase in open interest alongside falling prices suggests fresh short positions were initiated or long positions unwound, signalling bearish sentiment among traders.

Investor participation was strong, with delivery volumes spiking dramatically, indicating conviction in the prevailing trend. The derivatives activity, particularly the large notional value in options, points to complex hedging or speculative strategies aimed at capitalising on or protecting against further declines.

1 June: Technical Momentum Shifts to Sideways Amid Mixed Signals

On the same day, technical momentum for Alkem Laboratories shifted from mildly bearish to sideways, reflecting a complex interplay of bullish and bearish indicators. The stock traded near Rs.5,497.80, with intraday volatility ranging from Rs.5,475.70 to Rs.5,793.50, positioning it near its 52-week high of Rs.5,933.00.

Weekly MACD readings turned mildly bullish, suggesting improving short-term momentum, while monthly MACD remained mildly bearish, indicating longer-term caution. The Relative Strength Index (RSI) was neutral, and the Know Sure Thing (KST) indicator showed mild to strong bullishness on weekly and monthly charts respectively. Bollinger Bands suggested expanding bullish volatility, but daily moving averages remained mildly bearish, highlighting short-term resistance.

Volume indicators such as On-Balance Volume (OBV) were mildly bearish, indicating volume trends did not fully support price gains. Dow Theory assessments were mixed, mildly bearish weekly but mildly bullish monthly, underscoring the transitional technical environment. Despite these mixed signals, Alkem Laboratories outperformed the Sensex over multiple timeframes, including a 1.70% gain over the past week compared to the Sensex’s 0.85% decline.

2 June: Mildly Bearish Technical Shift Amid Market Volatility

On 2 June, the stock price declined further by 3.29% to Rs.5,239.10, reflecting a shift from sideways to mildly bearish technical momentum. The intraday range was Rs.5,282.50 to Rs.5,497.35, with the price moving closer to the lower end of its 52-week range. Daily moving averages turned bearish, signalling short-term downward pressure.

MACD indicators on weekly and monthly charts turned bearish or mildly bearish, confirming weakening momentum. Bollinger Bands on the weekly timeframe also turned bearish, with the price approaching the lower band, suggesting increased selling pressure. However, the Know Sure Thing (KST) indicator and Dow Theory assessments remained mildly bullish on monthly charts, indicating some underlying strength.

On-Balance Volume (OBV) showed no clear trend, implying volume did not decisively confirm the price decline. Despite this, Alkem Laboratories maintained strong relative performance against the Sensex, with year-to-date and longer-term returns significantly outperforming the benchmark.

3-5 June: Consolidation and Continued Pressure

From 3 to 5 June, Alkem Laboratories showed limited recovery and consolidation. On 3 June, the stock gained 0.71% to Rs.5,276.55, but this was followed by marginal declines on 4 and 5 June, closing at Rs.5,276.35 and Rs.5,251.25 respectively. The stock remained below key moving averages, with volumes declining, indicating reduced investor enthusiasm.

The Sensex fluctuated modestly during this period, with minor gains and losses, but Alkem Laboratories consistently underperformed the benchmark. The week closed with the stock down 4.48%, a sharper fall than the Sensex’s 0.78% decline, reflecting company-specific pressures and cautious investor sentiment.

Key Takeaways

Bearish Derivatives Activity: The 10.22% rise in open interest amid falling prices on 1 June signals increased bearish positioning and potential downside risk.

Mixed Technical Momentum: The stock’s technical profile shifted from mildly bearish to sideways and then to mildly bearish again, reflecting uncertainty and caution among investors.

Relative Underperformance: Alkem Laboratories declined 4.48% over the week, significantly underperforming the Sensex’s 0.78% fall, highlighting company-specific challenges.

Strong Long-Term Returns: Despite short-term weakness, the stock has delivered robust returns over 3, 5, and 10 years, outperforming the broader market consistently.

Mojo Score and Rating: The downgrade to a Sell rating with a Mojo Score of 38.0 reflects analyst caution amid mixed technical signals and sector headwinds.

Conclusion

Alkem Laboratories Ltd’s performance in the week ending 5 June 2026 was marked by a clear downward trajectory, driven by increased bearish derivatives activity and a shift in technical momentum towards caution. The stock’s 4.48% decline contrasted with the more modest 0.78% fall in the Sensex, underscoring company-specific pressures amid broader market volatility.

Technical indicators present a nuanced picture, with short-term bearish signals tempered by some longer-term bullish momentum. The elevated open interest and volume in derivatives suggest that traders are positioning for further downside or hedging existing exposures. Meanwhile, the company’s strong historical returns provide a backdrop of resilience, though the recent downgrade to a Sell rating advises prudence.

Investors should monitor key technical levels and volume trends closely in the coming weeks to assess whether the current bearish phase stabilises or intensifies. The mixed signals warrant a cautious approach, balancing the stock’s long-term strengths against near-term uncertainties within the Pharmaceuticals & Biotechnology sector.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →